ExAdEx-Innov Wins Descroix-Vernier EthicScience 2025 Award

ExAdEx-Innov Wins Descroix-Vernier EthicScience 2025 Award

ExAdEx-Innov has been awarded the prestigious Descroix-Vernier EthicScience 2025 Award in the « Prix du Jury – Espoir de la Recherche » category for its work in developing adipose tissue models for obesity research. 

 

This award, the only one in France dedicated to non-animal research and supported by Fondation Descroix-Vernier and Comité Scientifique Pro Anima recognizes innovative, rigorous research projects conducted without animal experimentation. It aims to encourage promising research and teams based on the exceptional quality of their work.

The award ceremony took place on March 28, 2025, at the French Senate, Palais du Luxembourg, Paris, when we have received a trophy and funding to continue our research.

The project « ObFAT-3D: 3D ex vivo human tissues to mimic obese adipose tissue » is based on our ExAdEx patented technology that closely reproduces the physiopathological responses of human adipose tissue. By combining transcriptomic and functional analyses, we aim to:

  • characterize the molecular signatures associated with obesity
  • generate a clinically relevant model of visceral adipose tissue
  • provide a reliable testing platform to anticipate the effects of pharmacological treatments.

 

« This award is a significant recognition of the scientific and medical potential of our work. It strengthens our commitment to more ethical research and accelerates our mission: to provide researchers and industry with revolutionary tools, directly usable in the laboratory and easily manipulable, to develop more effective and patient-adapted therapies more quickly« , says Vincent Dani.

ObFAT-3D project is co-funded by ExAdEx-Innov in collaboration with Institute of Molecular and Cellular Pharmacology (IPMC) team directed by Dr Bernard Mari and Dr Georges Vassaux, IdEx Innovation Program France 2030 of Université Côte d’Azur and the Association Nationale de la Recherche et de la Technologie (ANRT) funding of a CIFRE PhD program.

 

To read the program description: ObFAT-3D

Facebook
LinkedIn

Latest News

Poster session at IFSCC 2024 with Exsymol

Our Collaboration with Exsymol Monaco at the 34th Congress IFSCC Brazil 2024 We are excited to announce that our scientific research work performed in collaboration

KOL on adipose tissue biology.

Research Director (DR1 INSERM).
Team Leader of « Stem Cells and Differentiation » Lab at Institut de Biologie Valrose (Nice). 

Label of Laboratoire d’Excellence by the French National Research Agency (Investissements pour le Futur, Labex Signalife program). 

Co-inventor of 5 patents

Expert in clinical applications of adipose tissue.

Plastic Reconstructive and Aesthetic Surgeon in Nice.

Member of the Medical Council of Alpes Maritimes region.

Expert for the French National Regulatory Agency ANSM for medical devices.

Certified by French Health Autority HAS (2020-2024).

PhD thesis (2018) on fat tissue and adipose tissue stem cells grafting.

Expert in cell therapy and immunology. 

Senior Lecturer (Maitre de conférences).

Responsible of the Cell and Gene Therapy Unity of Nice University Hospital (CHU de Nice).

Director of « Micoralis » research team at Université Côte d’Azur (Nice).

Founder and CEO of the biotech company Biointerférence (2003-2006).

Co-inventor of 5 patents.

Vincent is responsible of company strategy and technological innovation, thanks to his double skill set in science and deeptech startup development.

With a deep knowledge and vision about ExAdEx technology, Vincent has actively worked as a deeptech entrepreneur to push further the development of breakthrough innovative products around human adipose tissue, which lead him to create ExAdEx-Inov. 

In addition to his entrepreneurial skills, Vincent has a strong background in biology (PhD in Cellular and Molecular Biology from Université Côte d’Azur) and training in clinical research management (CRA training at the Faculty of Medicine of La Timone, Marseille). 

He is co-inventor of the 2 company’s patent families. 

Main areas of expertise: DeepTech entrepreneur; Bioengineering of human adipose tissue. 

Luigi is responsible of the management of company operations and business development strategy, thanks to his expertise in biotech startup development.

With a double competence and training in business and science (including an MBA from IAE Paris Sorbonne Business School and a PhD in Cytological Sciences from Rome University La Sapienza), Luigi has been managing business development and R&D projects in a preclinical CRO and a biotech startup company in previous years. 

He has been supporting ExAdEx-Innov project and business development since his position as an Entrepreneur in Residence for CNRS Innovation Tech Transfer Office in 2021.

Main areas of expertise: Biotech Startup Business Development; Project management